HC Wainwright Reaffirms Hold Rating for Eyepoint Pharmaceuticals (NASDAQ:EYPT)

HC Wainwright reissued their hold rating on shares of Eyepoint Pharmaceuticals (NASDAQ:EYPT) in a report published on Friday, Stock Target Advisor reports.

Several other brokerages have also recently commented on EYPT. ValuEngine raised shares of Eyepoint Pharmaceuticals from a hold rating to a buy rating in a research report on Friday, January 3rd. Laidlaw began coverage on shares of Eyepoint Pharmaceuticals in a research report on Monday, November 4th. They issued a buy rating and a $5.00 price target for the company. Finally, Zacks Investment Research cut shares of Eyepoint Pharmaceuticals from a hold rating to a sell rating in a research report on Monday, January 6th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company’s stock. Eyepoint Pharmaceuticals has an average rating of Buy and an average price target of $3.95.

EYPT stock traded down $0.06 during midday trading on Friday, hitting $1.93. The company’s stock had a trading volume of 830,828 shares, compared to its average volume of 488,370. The company has a quick ratio of 4.29, a current ratio of 4.54 and a debt-to-equity ratio of 3.12. Eyepoint Pharmaceuticals has a 52-week low of $1.19 and a 52-week high of $2.82. The firm has a market capitalization of $215.15 million, a P/E ratio of -3.33 and a beta of 1.62. The firm has a 50-day simple moving average of $1.54 and a 200-day simple moving average of $1.66.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.15) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.01). Eyepoint Pharmaceuticals had a negative net margin of 409.07% and a negative return on equity of 250.32%. The business had revenue of $2.51 million during the quarter, compared to analysts’ expectations of $4.81 million. On average, sell-side analysts expect that Eyepoint Pharmaceuticals will post -0.54 earnings per share for the current fiscal year.

Several institutional investors have recently added to or reduced their stakes in EYPT. Wells Fargo & Company MN lifted its position in shares of Eyepoint Pharmaceuticals by 90.0% during the 2nd quarter. Wells Fargo & Company MN now owns 96,945 shares of the company’s stock worth $159,000 after purchasing an additional 45,922 shares during the last quarter. JPMorgan Chase & Co. purchased a new stake in shares of Eyepoint Pharmaceuticals during the 2nd quarter worth $28,000. Charles Schwab Investment Management Inc. lifted its position in shares of Eyepoint Pharmaceuticals by 882.3% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 143,409 shares of the company’s stock worth $236,000 after purchasing an additional 128,809 shares during the last quarter. Bank of New York Mellon Corp lifted its position in shares of Eyepoint Pharmaceuticals by 225.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 149,870 shares of the company’s stock worth $245,000 after purchasing an additional 103,857 shares during the last quarter. Finally, Northern Trust Corp lifted its position in shares of Eyepoint Pharmaceuticals by 44.9% during the 2nd quarter. Northern Trust Corp now owns 167,434 shares of the company’s stock worth $275,000 after purchasing an additional 51,919 shares during the last quarter. 56.86% of the stock is owned by institutional investors and hedge funds.

About Eyepoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States and Europe. It provides ILUVIEN for the treatment of diabetic macular edema; YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis (NIPU) that is in the Phase III clinical trials; and Retisert (fluocinolone acetonide intravitreal implant), a sustained-release implant for the treatment of posterior segment uveitis.

Further Reading: How to build a Fibonacci channel

Receive News & Ratings for Eyepoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyepoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.